Version 1
: Received: 22 February 2024 / Approved: 28 February 2024 / Online: 28 February 2024 (08:01:48 CET)
How to cite:
Chiappetta, C.; Della Rocca, C.; Di Cristofano, C. Advances in Target Therapy Research in Osteosarcoma. Preprints2024, 2024021596. https://doi.org/10.20944/preprints202402.1596.v1
Chiappetta, C.; Della Rocca, C.; Di Cristofano, C. Advances in Target Therapy Research in Osteosarcoma. Preprints 2024, 2024021596. https://doi.org/10.20944/preprints202402.1596.v1
Chiappetta, C.; Della Rocca, C.; Di Cristofano, C. Advances in Target Therapy Research in Osteosarcoma. Preprints2024, 2024021596. https://doi.org/10.20944/preprints202402.1596.v1
APA Style
Chiappetta, C., Della Rocca, C., & Di Cristofano, C. (2024). Advances in Target Therapy Research in Osteosarcoma. Preprints. https://doi.org/10.20944/preprints202402.1596.v1
Chicago/Turabian Style
Chiappetta, C., Carlo Della Rocca and Claudio Di Cristofano. 2024 "Advances in Target Therapy Research in Osteosarcoma" Preprints. https://doi.org/10.20944/preprints202402.1596.v1
Abstract
Osteosarcoma (OS) are the most prevalent malignant bone tumors in adolescents and young adults.. OS cells grow in a permissive local microenvironment which modulates their behavior and facilitates all steps in tumor development (e.g., proliferation/quiescence, invasion/migration, drug resistance) and contributes to their intrinsic heterogeneity. The lung parenchyma is the most common metastatic site in OS, and metastatic foci are frequently associated with a poor clinical outcome. Although multiple factors may be responsible for the disease, including genetic mutations (e.g., Rb, p53), the molecular mechanism of development of OS remains unclear and the conventional treatment for OS is still based on a sequential approach that combines chemotherapy and surgery. Also, despite the increase in clinical trials, the survival rates for OS have not improved. Non-specific targeting therapies thus show poor therapeutic effects with side effects at high doses. For these reasons, many efforts have been done to characterize the complex genome of osteosarcoma thanks to the whole exome analysis with the aim to identify predictive biomarkers to give to these patients a better therapeutic option.
This review aims to summarize and discuss the main recent advances in OS molecular research for precision medicine.
Keywords
Osteosarcoma; Next Generation Sequencing; Tumor targeted therapy; Immunotherapy
Subject
Medicine and Pharmacology, Pathology and Pathobiology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
